To the Editor—Whole-genome sequencing (WGS) analysis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to important findings related to the origin and evolution of the virus.1-3 The high potential for infectivity of SARS-CoV-2 raises legitimate concerns for person-to-person transmission, particularly in the hospital setting. Evaluation of the viral genome during a pandemic can aid in identifying outbreaks.4

To analyze local propagation of the virus, we relied upon direct comparisons of mutations found in viral genomes. We defined the dissimilarity between viral isolates as the size of the symmetric difference between the sets of mutations present relative to the reference genome. The analysis was restricted to the consensus level genome. The analysis was restricted to the consensus level genome. The analysis was restricted to the consensus level genome. The analysis was restricted to the consensus level genome.

Methods
Viral WGS was performed as previously described5 on all positive SARS-CoV-2 isolates at Children’s Hospital Los Angeles, a quaternary-care, free-standing, pediatric medical center.

To analyze local propagation of the virus, we relied upon direct comparisons of mutations found in viral genomes. We defined the dissimilarity between viral isolates as the size of the symmetric difference between the sets of mutations present relative to the reference genome. The analysis was restricted to the consensus level genome.

Table 1. Projections and Key Examples of ASP Involvement in COVID-19 Relief Efforts

| ASP Activity | Ways We Projected ASPs Might Be Utilized | Examples of ASP Utilization From March 2020 to March 2021 | Comments and Implications for the Future |
|--------------|-----------------------------------------|----------------------------------------------------------|------------------------------------------|
| Collaboration with epidemiology and infection prevention specialists | • Assisting in case identification | • As part of prospective audit and feedback efforts, ASPs played a role in early case identification. | • New mechanisms for real-time data access and distribution have been developed during the pandemic. | • ASPs and infection prevention programs can collaborate with IT departments to coordinate reporting. |
| Diagnostic Stewardship | • Assisting with SARS-CoV-2 test stewardship | • Identifying breakthrough cases after vaccination to send for sequencing | | • ASPs have longitudinal, enhanced access to leadership and should be involved in all future pandemic planning and response efforts. | • Outpatient relationships built out of necessity during the pandemic can be harnessed to augment ambulatory stewardship efforts. |
| Treatment | • Creating and monitoring compliance to treatment guidelines | • ASPs have played a major role in guideline creation, preauthorization of novel therapeutics as well as helping providers navigate therapeutic access. | | • ASPs should have longitudinal, enhanced access to leadership and should be involved in all future pandemic planning and response efforts. | • Outpatient relationships built out of necessity during the pandemic can be harnessed to augment ambulatory stewardship efforts. |

References
1. Stevens MP, Patel PK, Nori P. Involving antimicrobial stewardship programs in COVID-19 response efforts: all hands on deck. Infect Control Hosp Epidemiol 2020;41:744-745.
2. Banach DB, Johnston LB, Al Zubeidi, et al. Outbreak response and incident management: SHEA guidance and resources for healthcare epidemiologists in United States acute-care hospitals. Infect Control Hosp Epidemiol 2017;38:1393-1419.
3. Mazdeysana H, Nori P, Patel PK, et al. Antimicrobial stewardship at the core of COVID-19 response efforts: implications for sustaining and building programs. Curr Infect Dis Rep 2020;22:23.
4. Patel PK, Nori P, Stevens MP. Antimicrobial stewardship and bamlanivimab: opportunities for outpatient preauthorization? Infect Control Hosp Epidemiol 2020;41:744-745.
5. Stevens MP, Patel PK, Nori P. Antimicrobial stewardship programs and convalescent plasma for COVID-19: a new paradigm for preauthorization? Infect Control Hosp Epidemiol 2020. doi: 10.1017/ice.2020.459.
6. Nori P, Patel, PK, Stevens MP. Rational allocation of COVID-19 vaccines to healthcare personnel and patients: a role for antimicrobial stewardship programs? Infect Control Hosp Epidemiol 2020. doi: 10.1017/ice.2020.1393.

Utility of viral whole-genome sequencing for institutional infection surveillance during the coronavirus disease 2019 (COVID-19) pandemic

Alex Ryutov PhD1, Xiaowu Gai PhD1,2, Dejerianne Ostrow PhD1, Dennis T. Maglinte MS1, Jessica Flores BS1, Edaharine J. Salas MA3, Marisa Glucoft MPH3, Michael Smit MD2,3 and Jennifer Dien Bard PhD1,2

1Department of Pathology and Laboratory Medicine, Children’s Hospital Los Angeles, Los Angeles, California, 2Keck School of Medicine, University of Southern California, Los Angeles, California and 3Division of Infectious Diseases, Department of Pediatrics, Children’s Hospital Los Angeles, Los Angeles, California

© The Author(s), 2021. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America.
100× coverage (number of reads aligned to a genomic position) across 97% of the genome, were used for cluster analysis.

To analyze emerging groups of comparable isolates, we used hierarchical clustering. The dissimilarity matrix was defined as the sizes of symmetric differences between samples. We used the bottom-up unweighted pair group method with arithmetic mean reference (UPGMA) method with an R function hclust to visualize the clustering (Fig. 1). Suspected clusters that warranted investigation were internally defined by the institution’s contact-tracing program as (1) ≥2 SARS-CoV-2–positive cases within the same setting, (2) presence of an epidemiological link between the cases, noting the potential of prolonged close contact within 2 m (6 feet) for 15 minutes or longer, and (3) occurring within 14 days of symptom onset or positive SARS-CoV-2 reverse-transcriptase polymerase chain reaction (RT-PCR) test date if asymptomatic.

**Results**

**Establishment of protocol**

To determine a framework for interpreting dissimilarity between isolates, we compared pairwise differences between repeated samples from a single patient and within-family clusters with epidemiologically unrelated samples. The median pairwise difference between unrelated isolates estimated in the spring and early summer of 2020 was 10 mutations, and as of January 2021, it had increased to 16 mutations. The continued evolution of SARS-CoV-2 genome did not affect our analysis of local transmissions because suspect isolates were subjected to WGS within a relatively short period. Furthermore, the estimate of 0–1 variants between related samples becomes even more robust with increasing divergence between viral isolates.

Consequently, we adopted the following interpretation of pairwise and within-cluster dissimilarities: highly related = 0–1 variants; possibly related = 2–4 variants; probably unrelated = 5–9 variants; unrelated = 10 or more variants. Supplementary Figure 1 and Supplementary Table 1 (online) summarize the sample diversity and pairwise dissimilarities for 3 distinct periods. The 0–1-variant difference is statistically highly unlikely for 2 unrelated viral isolates, with $P = .00355$, based upon the combined data set.

**Institutional cluster analysis**

During a 9-month period (April–December 2020), we identified 25 potential clusters, involving a total of 70 SARS-CoV-2–positive individuals, that warranted further exploration by WGS. Of the 25 suspected clusters analyzed, conclusive results were available in 23 cases (92%) (Supplementary Table 2 online). We confirmed some relatedness in 14 clusters (56%) suspected by the contact-tracing team, including an outbreak within a unit. For example, clusters 1 and 2, corresponding to the same unit, were related to each other (Fig. 1 and Supplementary Table 2 online). We encountered cases in which relatedness was confirmed in only a portion of isolates within a suspected cluster. For example, cluster 20 consisted of 3 highly related isolates and 2 distinct isolates that were significantly distant (Fig. 1).

Importantly, WGS allowed us to rule out 9 highly suspicious clusters within the same units (36%), demonstrating that these were not healthcare-associated infections and that, during periods of high community incidence of coronavirus disease 2019 (COVID-19) cases, transmission outside the healthcare setting was a more likely driver of transmission events. The remaining samples were unresolved due to inadequate genome coverage.

**Discussion**

Similar to other studies, WGS analysis of SARS-CoV-2 isolates allowed us to monitor disease spread, to analyze outbreak dynamics, and to identify infection hot spots within our institution. Equally important was the capability provided by the WGS analysis to rule out suspected clusters and to confirm unrelated sources of infection. This capability not only allowed us to implement mitigation efforts with a more targeted approach but also provided us...
with insights about how our infection prevention and control strategies and use of personal protective equipment effectively prevented disease transmission.

There is currently a lack of standardization and definitions by local public health officials and regulatory bodies regarding the use of genomic epidemiology to identify clusters and hospital-acquired infections. We established a defined cut-off to determine relatedness based on the known mutation rate of SARS-CoV-2, which allowed us to accurately and conservatively interpret genomic data alongside clinical meta-data. We emphasize the need for clinical meta-data as part of the interpretation because 100% identical isolates with absolutely known association are commonly detected. We do recognize that WGS is not being pursued in many COVID-19 cases tested outside of our facility, and we emphasize the need for more widespread use of WGS given the utility of these data.

In conclusion, genomic analysis during COVID-19 pandemic, as well as other infectious diseases outbreaks, can be highly effective in a clinical setting as a complement to contact-tracing efforts, and WGS will become increasingly important in future pandemics.

Acknowledgments. We would like to acknowledge the Clinical Microbiology and Virology laboratory, Center for Personalized Medicine and the Infection Prevention and Control team at Children’s Hospital Los Angeles.

Financial support. This work was partially funded by The Saban Research Institute at Children’s Hospital Los Angeles intramural support for COVID-19 Directed Research to X.G. and J.D.B.

Conflict of interest. All authors report no conflicts of interest relevant to this article.

Supplementary material. To view supplementary material for this article, please visit https://doi.org/10.1017/ice.2021.185

References
1. da Silva Filipe A, Shepherd JG, Williams T, et al. Genomic epidemiology reveals multiple introductions of SARS-CoV-2 from mainland Europe into Scotland. Nat Microbiol 2021;6:112–122.
2. Gonzalez-Reiche AS, Hernandez MM, Sullivan MJ, et al. Introductions and early spread of SARS-CoV-2 in the New York City area. Science 2020;369:297–301.
3. Gudbjartsson DF, Helgason A, Jonsson H, et al. Spread of SARS-CoV-2 in the Icelandic population. N Engl J Med 2020;382:2302–2315.
4. Oude Munnink BB, Nieuwenhuijse DF, Stein M, et al. Rapid SARS-CoV-2 whole-genome sequencing and analysis for informed public health decision-making in the Netherlands. Nat Med 2020;26:1405–1410.
5. Pandey U, Yee R, Shen L, et al. High prevalence of SARS-CoV-2 genetic variation and D614G mutation in pediatric patients with COVID-19. Open Forum Infect Dis 2020. doi: 10.1093/ofid/ofaa551.
6. Galli T. dendextend: an R package for visualizing, adjusting and comparing trees of hierarchical clustering. Bioinformatics 2015;31:3718–3720.

Reinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B.1.1.7 variant in an immunocompromised adolescent

Lucila Marquez MD, MPH1,2, Tjin Koy MT, MPH, CIC2, Jennifer K. Spinler PhD3,4, Ruth Ann Luna PhD3,4, Lisa Tocco MPH, CIC2, Lea Fasciano MT, CIC2, James Dunn PhD3,5 and Judith R. Campbell MD1,2

1Department of Pediatrics, Section of Infectious Diseases, Baylor College of Medicine, Houston, Texas, 2Department of Infection Control and Prevention, Texas Children’s Hospital, Houston, Texas, 3Department of Pathology & Immunology, Baylor College of Medicine, Houston, Texas, 4Texas Children’s Microbiome Center, Department of Pathology, Texas Children’s Hospital, Houston, Texas and 5Department of Pathology, Texas Children’s Hospital, Houston, Texas

To the Editor—Infection with severe acute respiratory syndrome virus 2 (SARS-CoV-2) has resulted in >137 million cases globally and >31 million cases in the United States. Whether previous COVID-19 infection is protective against reinfection with original strains or SARS-CoV-2 genomic variants of concern remains unknown. Genomic variants were first reported in South Africa, the United Kingdom, and Brazil.1,2 Variant B.1.1.7 rapidly became the predominant variant in the United Kingdom within 3 months. It is more transmissible, and has caused increased cases and hospitalizations in several European countries.2 Community spread of the B.1.1.7 variant has resulted in >16,000 cases in the United States since first being reported in December 2020 in travelers from the United Kingdom.2,4–5 Cases of the B.1.1.7 variant are likely underreported in the United States, and the increasing prevalence of this variant in communities adds complexity to the public health and infection control response.4–5 This report illustrates challenges associated with reinfection in hospitalized patients and the importance of genomic sequencing in the evaluation of possible SARS-CoV-2 reinfection.

Methods
Case investigation
In November 2020, a 16-year-old with end-stage renal disease due to focal segmental glomerulosclerosis was electively admitted to our hospital for a trial off hemodialysis. At the time of admission, a nasopharyngeal swab was negative for detection of SARS-CoV-2 by reverse-transcriptase polymerase chain reaction (RT-PCR). On hospital day 2, the patient complained of a sore throat. She had recent exposure to an ill family member, thus repeat testing for SARS-CoV-2 was performed and was positive; cycle threshold (CT) values for E and S genes were 32.4 and 32.0, respectively. Other symptoms included fatigue, nasal congestion, rhinorrhea, and a nonproductive cough. She remained afebrile and did not

Author for correspondence: Judith R. Campbell, E-mail: judithc@bcm.edu
Cite this article: Marquez L, et al. (2022). Reinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B.1.1.7 variant in an immunocompromised adolescent. Infection Control & Hospital Epidemiology. 43: 1088–1090, https://doi.org/10.1017/ice.2021.195

© The Author(s), 2021. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America.